Liver and Inflammatory Biomarkers Are Related to High Mortality in Hospitalized Patients with COVID-19 in Brazilian Amazon Region

Overview

Journal Life (Basel)

Specialty Biology

Date 2024 Jul 27

PMID 39063622

Authors

Carla Sousa da Silva

Katrini Guidolini Martinelli

Marlison Wesley Miranda Viana

Deliane Dos Santos Soares

Yasmin Garcia Silva Correa

Lucas Lima da Silva

Vanessa Salete de Paula

Luana Lorena Silva Rodrigues

Livia Melo Villar

Affiliations

Soon will be listed here.

Abstract

COVID-19 is a multisystem disease with many clinical manifestations, including liver damage and inflammation. The objective of this study is to analyze inflammation biomarkers in relation to the clinical outcome and respiratory symptoms of COVID-19. This is a retrospective cohort of patients with COVID-19 admitted to the Hospital Regional do Baixo Amazonas from 2020 to 2022. Data were collected from electronic medical records from admission to the 30th day of hospitalization and soon after hospital discharge. A total of 397 patients were included in the study. In the longitudinal follow-up of liver markers, a significant difference was found for AST on day 14, with a higher median in the death group. Among the hematological markers, lymphopenia was observed throughout the follow-up, with the death group having the most altered values. When comparing the evolution of biomarkers in the Non-Invasive Ventilation (NIV) and Invasive Mechanical Ventilation (IMV) groups, AST showed a significant difference only on day 14 and GGT on day 1, being greater in the IMV group, and indirect bilirubin on day 7 being more altered in the NIV group. In conclusion, death during hospitalization or a more severe form of COVID-19 was related to significant changes in liver and inflammatory biomarkers.

References

Buffon M, Severo I, Barcellos R, Azzolin K, Lucena A . Critically ill COVID-19 patients: a sociodemographic and clinical profile and associations between variables and workload. Rev Bras Enferm. 2022; 75Suppl 1(Suppl 1):e20210119. DOI: 10.1590/0034-7167-2021-0119. View

Amin M . COVID-19 and the liver: overview. Eur J Gastroenterol Hepatol. 2020; 33(3):309-311. PMC: 7846245. DOI: 10.1097/MEG.0000000000001808. View

Spearman C, Aghemo A, Valenti L, Sonderup M . COVID-19 and the liver: A 2021 update. Liver Int. 2021; 41(9):1988-1998. DOI: 10.1111/liv.14984. View

van Halem K, Bruyndonckx R, van der Hilst J, Cox J, Driesen P, Opsomer M . Risk factors for mortality in hospitalized patients with COVID-19 at the start of the pandemic in Belgium: a retrospective cohort study. BMC Infect Dis. 2020; 20(1):897. PMC: 7691970. DOI: 10.1186/s12879-020-05605-3. View

Silva M, Silva D, Gomes de Macedo Bacurau A, Francisco P, de Assumpcao D, Neri A . Ageism against older adults in the context of the COVID-19 pandemic: an integrative review. Rev Saude Publica. 2021; 55:4. PMC: 8023321. DOI: 10.11606/s1518-8787.2021055003082. View

Diaz-Louzao C, Barrera-Lopez L, Lopez-Rodriguez M, Casar C, Vazquez-Agra N, Pernas-Pardavila H . Longitudinal relationship of liver injury with inflammation biomarkers in COVID-19 hospitalized patients using a joint modeling approach. Sci Rep. 2022; 12(1):5547. PMC: 8972986. DOI: 10.1038/s41598-022-09290-x. View

Bloom P, Meyerowitz E, Reinus Z, Daidone M, Gustafson J, Kim A . Liver Biochemistries in Hospitalized Patients With COVID-19. Hepatology. 2020; 73(3):890-900. DOI: 10.1002/hep.31326. View

Olavegogeascoechea P, Gallardo Martinez A, Scapellato J, Federico A . Epidemiological and clinical characteristics of survivors of SARS-COV-2 infection: A descriptive study. Medwave. 2022; 22(9):e2581. DOI: 10.5867/medwave.2022.09.2581. View

Yang L, Liu S, Liu J, Zhang Z, Wan X, Huang B . COVID-19: immunopathogenesis and Immunotherapeutics. Signal Transduct Target Ther. 2020; 5(1):128. PMC: 7381863. DOI: 10.1038/s41392-020-00243-2. View

10.

Hanlon P, Chadwick F, Shah A, Wood R, Minton J, McCartney G . COVID-19 - exploring the implications of long-term condition type and extent of multimorbidity on years of life lost: a modelling study. Wellcome Open Res. 2021; 5:75. PMC: 7927210. DOI: 10.12688/wellcomeopenres.15849.3. View

11.

Kaye R, Chang C, Kazahaya K, Brereton J, Denneny 3rd J . COVID-19 Anosmia Reporting Tool: Initial Findings. Otolaryngol Head Neck Surg. 2020; 163(1):132-134. DOI: 10.1177/0194599820922992. View

12.

Xu S, Ilyas I, Weng J . Endothelial dysfunction in COVID-19: an overview of evidence, biomarkers, mechanisms and potential therapies. Acta Pharmacol Sin. 2022; 44(4):695-709. PMC: 9574180. DOI: 10.1038/s41401-022-00998-0. View

13.

Nascimento J, Gomes B, Carmo Junior P, Petriz J, Rizk S, Costa I . COVID-19 and Hypercoagulable State: A New Therapeutic Perspective. Arq Bras Cardiol. 2020; 114(5):829-833. PMC: 8386998. DOI: 10.36660/abc.20200308. View

14.

Harapan H, Fajar J, Supriono S, Soegiarto G, Wulandari L, Seratin F . The prevalence, predictors and outcomes of acute liver injury among patients with COVID-19: A systematic review and meta-analysis. Rev Med Virol. 2021; 32(3):e2304. PMC: 8646502. DOI: 10.1002/rmv.2304. View

15.

Oliveira W, Duarte E, Araujo de Franca G, Garcia L . How Brazil can hold back COVID-19. Epidemiol Serv Saude. 2020; 29(2):e2020044. DOI: 10.5123/s1679-49742020000200023. View

16.

Ejaz R, Ashraf M, Qadeer S, Irfan M, Azam A, Butt S . Gender-based incidence, recovery period, and mortality rate of COVID-19 among the population of district Attock, Pakistan. Braz J Biol. 2021; 83:e249125. DOI: 10.1590/1519-6984.249125. View

17.

Gholizadeh P, Safari R, Marofi P, Zeinalzadeh E, Pagliano P, Ganbarov K . Alteration of Liver Biomarkers in Patients with SARS-CoV-2 (COVID-19). J Inflamm Res. 2020; 13:285-292. PMC: 7335895. DOI: 10.2147/JIR.S257078. View

18.

Phipps M, Barraza L, LaSota E, Sobieszczyk M, Pereira M, Zheng E . Acute Liver Injury in COVID-19: Prevalence and Association with Clinical Outcomes in a Large U.S. Cohort. Hepatology. 2020; 72(3):807-817. PMC: 7300739. DOI: 10.1002/hep.31404. View

19.

Orellana J, Cunha G, Marrero L, Horta B, da Costa Leite I . Explosion in mortality in the Amazonian epicenter of the COVID-19 epidemic 19. Cad Saude Publica. 2020; 36(7):e00120020. DOI: 10.1590/0102-311x00120020. View

20.

Gato S, Lucena-Valera A, Munoz-Hernandez R, Sousa J, Romero-Gomez M, Ampuero J . Impact of COVID-19 on liver disease: From the experimental to the clinic perspective. World J Virol. 2021; 10(6):301-311. PMC: 8641041. DOI: 10.5501/wjv.v10.i6.301. View